Pariser Minister: 'Anfang vom Ende der Arroganz von Monsanto-Bayer' (Seite 22) | Diskussion im Forum

[faultcode]

25.4.
Bayer übertrifft Erwartungen im 1. Quartal - Aktie gewinnt
https://www.finanzen.net/nachricht/aktien/rueckstellungen-ba…

=>
...Der bereinigte operative Gewinn (EBITDA) legte um 44,6 Prozent auf 4,188 Milliarden Euro zu, wie der Konzern aus Leverkusen bei Vorlage der ersten Zwischenbilanz dieses Jahres mitteilte. Analysten hatten nur 4,027 Milliarden Euro erwartet.

Überwiegend ist der rasante Zuwachs, der sich in gleicher Weise auch im Umsatz zeigte, auf den Monsanto-Konzern zurückzuführen, den Bayer im vergangenen Sommer übernommen hat.


Rückstellungen für den geplanten massiven Personalabbau und die Kosten eines Vergleichs um die Nebenwirkungen des Blutverdünners Xarelto sowie die Akquisition von Monsanto belasteten das weitere Ergebnis.

Unter dem Strich ging der Konzerngewinn um 36,5 Prozent zurück auf 1,241 Milliarden Euro. Das bereinigte Ergebnis je Aktie erhöhte sich dagegen trotz der gestiegenen Aktienanzahl um 13,8 Prozent auf 2,55 Euro. Hier hatten Analysten Bayer 5 Cent weniger zugetraut.


Bislang ohne Folgen für das Ergebnis sind die Prozesse um den Monsanto-Unkrautvernichter Roundup und dessen angeblich krebserregende Wirkung in den USA, die den Konzern und die Börse seit Monaten in Atem halten. Allerdings verklagen immer mehr US-Bürger den Konzern: Inzwischen liegen 13.400 Klagen in Leverkusen vor, 11.200 waren es Ende Januar.


Die Jahresprognose bestätigte Bayer. Danach soll der Umsatz um 4 Prozent auf 46 Milliarden Euro, das bereinigte EBITDA auf 12,2 Milliarden und das bereinigte Ergebnis je Aktie auf 6,80 Euro steigen....

[faultcode]

MM 2019/05 zu Bayer und Baumann:

• Vergleich mit den Klägern erst, wenn die Stimmung bei den US-Gerichten kippt (so der Plan der Unternehmensverwaltung)

• Unternehmensverwaltung setzt darauf, daß höhere US-Instanzen mit Profi-Richtern die bisherigen Laien-Jury-Schuldsprüche "korrigieren"

• Wollburg & Habersack sagen in ihren jeweiligen Gutachten, Bayer hätte eingehend und fortlaufend die Risiken der Monsanto-Übernahme geprüft bzw. überprüfen lassen (zwecks der vielen anvisierten Nicht-Entlastungen zur HV)

• AR-Chef Wenning hält nichts von einer Aufspaltung von Bayer

[faultcode]

Antwort auf Beitrag Nr.: 60.277.668 von faultcode am 04.04.19 15:05:02

1.4.
Costco Drops Roundup Weedkiller After $80 Million Awarded In Second Cancer Case
https://www.zerohedge.com/news/2019-04-01/costco-drops-round…

[faultcode]

Cyber-Attacke bei Bayer - Schaden noch nicht absehbar

https://www.finanzen.net/nachricht/aktien/hackergruppe-34-wi…

=>
...Das Cyber Defense Center von Bayer habe Anfang 2018 den Angriff durch die Hackergruppe "Winnti" festgestellt und umfangreiche Analysen gestartet, teilte der Pharma- und Agrarchemiekonzern am Donnerstag mit. Es gebe keine Evidenz für einen Datenabfluss.

Die Höhe des entstandenen Schadens sei noch nicht absehbar, sagte ein Konzern-Sprecher. Die Ermittlungen der Staatsanwaltschaft Köln seien noch am Laufen. Über die Cyberattacke hatten zuerst der Bayerische und der Norddeutsche Rundfunk berichtet.

Nach Angaben von Bayer haben die Experten des Cyber Defense Centers die betroffenen Systeme identifiziert, analysiert und bereinigt. Sie hätten dabei eng mit der Deutschen Cyber-Sicherheitsorganisation (DCSO) sowie dem Landeskriminalamt in Nordrhein-Westfalen zusammengearbeitet. Wann genau die Hacker Zugriff auf das Netzwerk von Bayer erlangten, sei unklar, sagte der Sprecher. Sie hätten diesen aber unter Beobachtung bis Ende März dieses Jahres gehabt.

"Die infizierten Systeme hat unser Cyber Defense Center bewusst zunächst nicht bereinigt, um potenzielle Kommunikation der Angreifer analysieren zu können", erklärte Bayer. Ende März seien dann alle Systeme bereinigt worden. Bis dahin seien die Hacker nicht aktiv geworden....

[faultcode]

Antwort auf Beitrag Nr.: 60.229.966 von faultcode am 29.03.19 14:54:21

Germany's Bayer banks on rising pet demand for sustained growth

29.3.
http://www.chinadaily.com.cn/a/201903/29/WS5c9d8976a31048422…

=>
Bayer AG, the Germany-based pharmaceutical and life sciences major, is banking on the growing demand for pets in China in the next five years to provide ample growth opportunities for the company in the pet care market.

Average spending on pets in China has risen in the last few years, thanks to the growing mid-income population in the country. According to an industry report from Goumin.com, a portal that tracks the pet community, the average annual spending on a pet dog or cat was 5,016 yuan ($746.6) in 2018, up 15 percent from the corresponding period in 2017.

Bayer, the company behind the top-selling pet deworming pills Drontal, said that increased pet spending and the desire to have more pets would be the main growth drivers for the company.

"China is the third-largest pet-owning country in the world, and China's pet industry is growing rapidly," said Christoph Vetten, head of Bayer Animal Health Greater China, during the launch of its flea and tick collar product Seresto in Beijing in March.

Liu Bin, manager of the pet department of Bayer Animal Health in China, said that nearly 17 percent of the Chinese households owned dogs and 9 percent cats, and the same is expected to grow to 27 percent and 22 percent by 2022.

Seresto, which is priced at around 250 yuan, is three to four times costlier than other products in the market. Vetten, however, remained confident that the product would become popular in China.

Han Jing, owner of Meowland, a Shanghai-based cat breeder, has already started to stock the products on the day it was launched.

The consumer market for pet dogs and cats reached 170.9 million yuan in 2018 in China, a 27 percent annual growth, while the number of dogs and cats in China topped 91.49 million, according to industry sources. Chinese pet owners on average spent 1,826.7 yuan per dog and 1,721.2 yuan per cat for pet supplies in 2018, with toys, collars and cat litters among the most popular categories.

In a market that is tremendous yet still growing, the current supply is still short of demand.

Sun Yanzheng, a senior veterinary doctor at the Veterinary Teaching Hospital of China Agricultural University, said though the number of pet owners in China has been rising, health product and medicine suppliers for pets were far from meeting the demand.

"The development of the pet industry in China is way faster than the United States," said Sun. "The industry has grown by 4 to 5 percent in the past 10 years in the US, but the pace will be no slower than 15 percent in China in the next decade."

Though the pet care market has been growing, it is not the case with the pet healthcare industry.

"The pets' medical care industry accounts for 50 percent of the pet business in the US, but only 20 percent in China," Sun said. "The pet medical workers in the market are not qualified enough, as most of them were previously livestock veterinary professionals."

[WernaWillsWissen]

Antwort auf Beitrag Nr.: 60.229.966 von faultcode am 29.03.19 14:54:21

Zitat von faultcode: 29.3.
https://www.finanzen.net/nachricht/aktien/monsanto-klagen-be…

=>
...Zwar seien einzelne Mitarbeiter beunruhigt. "Wir haben aber weiter Vertrauen in den Vorstand, dass die strategische Entscheidung, Monsanto zu übernehmen, richtig war", sagte der stellvertretende Chef des Gesamtbetriebsrats, Heinz-Georg Webers, der "Rheinischen Post" (Freitag).

"Wir hoffen, dass Bayer sich in den Berufungsverfahren durchsetzen kann. Bayer ist erfahren mit Produkthaftungsklagen."...

... und am Ende werden dann doch wieder in DE die teuersten Arbeitsplätze in Forschung, Entwicklung und Verwaltung abgebaut, damit man die Schadenersatzforderungen auch bezahlen kann!:P

Würde mich wundern wenn es anders käme ... ach wurde ja schon so zum Teil beschlossen!

WWW

[faultcode]

Antwort auf Beitrag Nr.: 60.224.671 von faultcode am 29.03.19 02:13:59

Betriebsrat stärkt Bayer-Chef Baumann den Rücken

29.3.
https://www.finanzen.net/nachricht/aktien/monsanto-klagen-be…

=>
...Zwar seien einzelne Mitarbeiter beunruhigt. "Wir haben aber weiter Vertrauen in den Vorstand, dass die strategische Entscheidung, Monsanto zu übernehmen, richtig war", sagte der stellvertretende Chef des Gesamtbetriebsrats, Heinz-Georg Webers, der "Rheinischen Post" (Freitag).

"Wir hoffen, dass Bayer sich in den Berufungsverfahren durchsetzen kann. Bayer ist erfahren mit Produkthaftungsklagen."...

[faultcode]

Antwort auf Beitrag Nr.: 60.214.163 von faultcode am 27.03.19 23:44:10

The States In America That Use The Most (And Least) Glyphosate

28.3.
https://www.zerohedge.com/news/2019-03-27/state-america-use-…

=>

[faultcode]

Antwort auf Beitrag Nr.: 60.193.331 von faultcode am 25.03.19 23:15:40

Jury awards million in damages to man who says Monsanto’s Roundup caused his cancer

27.3.
https://www.marketwatch.com/story/jury-awards-80-million-in-…

=>
...A federal jury on Wednesday awarded $80 million in damages to a California man who blamed Roundup weed killer for his cancer, in a case that his attorneys say could help determine the fate of hundreds of similar lawsuits.

The six-person jury in San Francisco returned its verdict in favor of Edwin Hardeman, 70, who said he used Roundup products to treat poison oak, overgrowth and weeds on his San Francisco Bay Area property for years. The same jury previously found that Roundup was a substantial factor in Hardeman’s non-Hodgkin’s lymphoma.

Agribusiness giant Monsanto said studies have established that the active ingredient in its widely used weed killer, glyphosate, is safe. The company said it will appeal.

“We are disappointed with the jury’s decision, but this verdict does not change the weight of over four decades of extensive science and the conclusions of regulators worldwide that support the safety of our glyphosate-based herbicides and that they are not carcinogenic,” according to a statement from Bayer, which acquired Monsanto last year.

A different jury in August awarded another man $289 million, but a judge later slashed it to $78 million. Monsanto has appealed.

Hardeman’s trial may be more significant than that case. U.S. Judge Vince Chhabria is overseeing hundreds of Roundup lawsuits and has deemed Hardeman’s case and two others “bellwether trials.”

The outcome of such cases can help attorneys decide whether to keep fighting similar lawsuits or settle them. Legal experts said verdicts in favor of Hardeman and the other test plaintiffs would give their attorneys a strong bargaining position in any settlement talks for the remaining cases before Chhabria.

Many government regulators have rejected a link between cancer and glyphosate. Monsanto has vehemently denied such a connection, saying hundreds of studies have established that the chemical is safe.

Monsanto developed glyphosate in the 1970s, and the weed killer is now sold in more than 160 countries and widely used in the U.S.

The herbicide came under increasing scrutiny after the France-based International Agency for Research on Cancer, which is part of the World Health Organization, classified it as a “probable human carcinogen” in 2015.

Lawsuits against Monsanto followed, and thousands are now pending nationwide.

Monsanto has attacked the international research agency’s opinion as an outlier. The U.S. Environmental Protection Agency says glyphosate is safe for people when used in accordance with label directions.

[faultcode]

Bayer and Johnson & Johnson Settle Lawsuits Over Xarelto, a Blood Thinner, for $775 Million

25.3.
https://www.nytimes.com/2019/03/25/health/xarelto-blood-thin…

=>
The settlement resolves about 25,000 lawsuits, which claimed the companies failed to warn about deadly bleeding episodes caused by the drug.

Johnson & Johnson and Bayer said on Monday that they had agreed to pay $775 million to settle about 25,000 lawsuits involving the blood thinner Xarelto, which they jointly sell.


The settlement, which will be split evenly between the two companies, resolves state and federal cases in which patients sued the companies for failing to warn about potentially fatal bleeding episodes when patients took the drug.


Neither company admitted liability, and each noted that the companies had prevailed in the six lawsuits that went to trial. In a statement, Janssen, the pharmaceutical division of Johnson & Johnson, said it was settling because such complex litigation “demands an enormous amount of time and resources.” It added: “What’s the bottom line? We stand behind Xarelto and are eager and excited to move forward.”

In a separate statement, Bayer said, “We remain committed to the more than 45 million patients who have been prescribed Xarelto worldwide.”

“This is a fair and just resolution for thousands of consumers who have substantial claims,” Andy Birchfield of Beasley Allen, the co-lead counsel of the plaintiff’s steering committee for the federal legislation, said in a statement.


Xarelto is one of a new group of blood thinners intended to replace warfarin, a widely used and decades-old drug that required frequent blood tests and a strict diet. Xarelto, along with similar drugs like Eliquis and Pradaxa, did not require such tests.

Lawyers for the patients had argued that the companies failed to warn patients that Xarelto, which thins the blood to prevent clots that lead to strokes, could trigger massive bleeding in some people, leading to deaths and serious injury. The bleeding episodes didn’t always respond to standard treatments and, for years, there was no specific antidote to bleeding caused by Xarelto and the other new drugs.

Last year, the Food and Drug Administration approved such an antidote, Andexxa, that can help stop the bleeding in patients who take Xarelto and Eliquis, which is sold by Pfizer and Bristol-Myers Squibb.


But Bayer and Johnson & Johnson stood by Xarelto, citing large-scale clinical trials that showed the drug was safe and effective.

Lawyers for the plaintiffs in the Xarelto lawsuits had previously raised questions about whether the clinical trial that led to the drug’s approval was flawed because a blood-testing monitor that was used in the study was later found to be faulty, possibly skewing the results. The F.D.A. later concluded that the problems with the monitor did not affect the trial’s outcome.


In 2014 the German drug maker Boehringer Ingelheim agreed to pay $650 million to settle about 4,000 lawsuits over a similar drug, Pradaxa, which was also blamed in bleeding deaths and injuries.

Xarelto, which is also known as rivaroxaban, was among Johnson & Johnson’s top-selling products in 2018, bringing in nearly $2.5 billion in revenues, although its sales fell slightly last year compared with 2017, according to its annual filings.